78 related articles for article (PubMed ID: 28099265)
1. Observer agreement of treatment responses on planar bone scintigraphy in prostate cancer patients: importance of the lesion assessment method.
Fonager RF; Zacho HD; Albertsen S; Fledelius J; Ejlersen JA; Christensen MH; Aleksyniene R; Biurrun Manresa JA; Petersen LJ
Nucl Med Commun; 2017 Mar; 38(3):215-221. PubMed ID: 28099265
[TBL] [Abstract][Full Text] [Related]
2. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
3. Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer.
Zacho HD; Manresa JA; Mortensen JC; Bertelsen H; Petersen LJ
Nucl Med Commun; 2015 May; 36(5):445-51. PubMed ID: 25646705
[TBL] [Abstract][Full Text] [Related]
4. Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels.
Pricolo P; Ancona E; Summers P; Abreu-Gomez J; Alessi S; Jereczek-Fossa BA; De Cobelli O; Nolè F; Renne G; Bellomi M; Padhani AR; Petralia G
Cancer Imaging; 2020 Oct; 20(1):77. PubMed ID: 33109268
[TBL] [Abstract][Full Text] [Related]
5. Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study.
Sadik M; Suurkula M; Höglund P; Järund A; Edenbrandt L
J Nucl Med; 2009 Mar; 50(3):368-75. PubMed ID: 19223423
[TBL] [Abstract][Full Text] [Related]
6. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
7. Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography.
Schirrmeister H; Buck A; Guhlmann A; Reske SN
Thyroid; 2001 Jul; 11(7):677-83. PubMed ID: 11484897
[TBL] [Abstract][Full Text] [Related]
8. Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastases.
Zacho HD; Aleksyniene R; Ejlersen JA; Fledelius J; Petersen LJ
Nucl Med Commun; 2020 Oct; 41(10):1005-1009. PubMed ID: 32694282
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.
Zacho HD; Barsi T; Mortensen JC; Mogensen MK; Bertelsen H; Josephsen N; Petersen LJ
Clin Nucl Med; 2014 Jan; 39(1):26-31. PubMed ID: 24217537
[TBL] [Abstract][Full Text] [Related]
10. Reliability of X-rays and bone scans for the assessment of changes in skeletal metastases from breast cancer.
Shackleton M; Yuen K; Little AF; Schlicht S; McLachlan SA
Intern Med J; 2004 Nov; 34(11):615-20. PubMed ID: 15546455
[TBL] [Abstract][Full Text] [Related]
11. Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
Anand A; Morris MJ; Kaboteh R; Båth L; Sadik M; Gjertsson P; Lomsky M; Edenbrandt L; Minarik D; Bjartell A
J Nucl Med; 2016 Jan; 57(1):41-5. PubMed ID: 26315832
[TBL] [Abstract][Full Text] [Related]
12. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
14. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.
Fuccio C; Castellucci P; Schiavina R; Santi I; Allegri V; Pettinato V; Boschi S; Martorana G; Al-Nahhas A; Rubello D; Fanti S
Ann Nucl Med; 2010 Jul; 24(6):485-92. PubMed ID: 20544323
[TBL] [Abstract][Full Text] [Related]
15. 11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer.
Strandberg S; Karlsson CT; Ogren M; Axelsson J; Riklund K
Anticancer Res; 2016 Dec; 36(12):6475-6479. PubMed ID: 27919970
[TBL] [Abstract][Full Text] [Related]
16. Whole-body bone SPECT in breast cancer patients: the future bone scan protocol?
Abikhzer G; Gourevich K; Kagna O; Israel O; Frenkel A; Keidar Z
Nucl Med Commun; 2016 Mar; 37(3):247-53. PubMed ID: 26528786
[TBL] [Abstract][Full Text] [Related]
17. VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.
Ishii S; Kikuchi K; Miyajima M; Sakuma K; Shishido F
Fukushima J Med Sci; 2015; 61(1):23-31. PubMed ID: 25946906
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer.
Cook GJ; Venkitaraman R; Sohaib AS; Lewington VJ; Chua SC; Huddart RA; Parker CC; Dearnaley DD; Horwich A
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):7-13. PubMed ID: 20697891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
